PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Somatrogon - Growth failure - children

PAD Profile : Somatrogon - Growth failure - children

Keywords :
Growth failure, shared care, NICE
Brand Names Include :
Ngenla

Traffic Light Status

Status 1 of 2.

Status :
Amber
Formulations :
  • Injection
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :
Type
Document
Review Date

Status 2 of 2.

Status :
N/A
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 August 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

.The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the reviewed AMBER shared care document for Recombinant human growth hormone for children and young people.

01 March 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends somatrogon as a treatment option for the treatment of growth disturbance caused by growth hormone deficiency in children and young people aged 3 years and over in line with NICE TA863

Somatrogon will be considered AMBER on the traffic light system 

Patients should not be referred for a switch to somatrogon from other growth hormone preparations but can consider switch on discussion with the specialist team at their next routine follow up appointment.

Associated BNF Codes

06. Endocrine System
06.05.01. Hypothalamic & anterior pituitary hormone & antioestrogens
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More